Last checked at 10 Jul 2023 07:00
10 July 2023
Assura plc
Scrip Dividend Declaration & Additional Listing
Assura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that 1,663,495 new Ordinary Shares ("the New Shares") have been issued pursuant to the Scrip Dividend Scheme (1,376,254) and the Performance Share Plan (287,241).
Application has therefore been made for the admission of the New Shares to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange's market for listed securities ("Admission"). The New Shares will rank pari passu with the Company's existing ordinary shares and Admission is expected to occur at 8.00am on 12 July 2023.
Following the allotment of the New Shares, it is expected that the total number of shares in issue will be 2,965,311,611 (none of which will be held in treasury) and that, accordingly, the total number of voting rights of the Company will be 2,965,311,611.
Scrip dividend scheme
Pursuant to the Scrip Dividend Scheme and in response to the scrip dividend alternative for the quarterly interim dividend payable on 12 July 2023 (the "Scrip Dividend Alternative"), elections were received in respect of 2.84 per cent. of the Company's Ordinary Shares in issue as at the record date of 9 June 2023.
Electing shareholders will receive ordinary shares in the Company ("Shares") in lieu of cash in respect of this dividend and, accordingly 1,376,254 Shares will be issued by the Company to such shareholders.
Copies of the documents relating to the Scrip Dividend Alternative are available for inspection through the National Storage Mechanism (https://data.fca.org.uk/#/nsm/nationalstoragemechanism).
This interim dividend is 100% Property Income Distribution ("PID"). Forms to register for gross PIDs (on future interim dividends) are available on the Company's website. Please click here for PID Forms.
Performance Share Plan
A further 287,241 new Ordinary Shares have been issued to the Assura plc Employee Benefit Trust in order to satisfy the awards pursuant to the 2020 Performance Share Plan.
- ENDS -
For more information, please contact:
Assura plc Orla Ball, General Counsel David Purcell, Investor Relations Director | Tel: 01925 945354 Email: Investor@assura.co.uk |
FGS Global Gordon SimpsonJames Thompson | Tel: 0207 251 3801 Email: Assura@fgsglobal.com |
Notes to Editors
Assura plc is a national healthcare premises specialist and UK REIT based in Altrincham, UK - caring for more than 600 primary healthcare buildings, from which almost seven million patients are served.
A constituent of the FTSE 250 and the EPRA* indices, as at 31 March 2023, Assura's portfolio was valued at £2.7 billion.
At Assura, we BUILD for health. Assura builds better spaces for people and places, invests in skills and inspires new ways of working, and unlocks the power of design and innovation to deliver lasting impact for communities - aiming for six million people to have benefitted from improvements to and through its healthcare buildings by 2026.
Assura is leading for a sustainable future, targeting net zero carbon across its portfolio by 2040.
Further information is available at www.assuraplc.com
Assura plc LEI code: 21380026T19N2Y52XF72
*EPRA is a registered trademark of the European Public Real Estate Association.